U.S. health authorities are signing off on human trials of CBD to treat opioid addiction. The U.S. Food and Drug Administration gave the green light this week to Ananda Scientific to start human testing of its CBD drug Nantheia ATL5, the company announced. The trials will be run out of UCLA and are funded by
Curaleaf
U.S. District Court for the Eastern District of New York Crediting the CBD company’s forthrightness, a federal judge in New York federal judge has dismissed a lawsuit against Massachusetts-based Curaleaf from investors who argued the company misled them about legality of its CBD products. The investors sued when Curaleaf’s share price fell in 2019 after